Key result
Ezetimibe monotherapy for 3 months significantly reduced LDL-C levels by an average of 1.6 mmol/L (21.3%) from baseline in children with heterozygous familial hypercholesterolemia.
Why the study?
Heterozygous familial hypercholesterolemia carries a high risk of early cardiovascular events, warranting real-world evaluation of ezetimibe efficacy and safety, alone and combined with statins, in children and adolescents.
Does ezetimibe monotherapy reduce LDL-C levels in children and adolescents with heterozygous familial hypercholesterolemia?
Population
130 children with dyslipidaemia (average age 13.2 ± 3.1 years)
Comparison
Ezetimibe monotherapy vs ezetimibe and atorvastatin combination therapy
Design
Retrospective descriptive analysis study
Authors
Loading...
Supports ezetimibe in pediatric heFH; hypothesis-generating and requires prospective RCTs before practice change.
Observational (n=130)
No
Does ezetimibe monotherapy reduce LDL-C levels in children and adolescents with heterozygous familial hypercholesterolemia?
Mean Difference: -1.6
Absolute Event Rate: 4.5% vs 5.6%
p-value: p=<0.05
Ezetimibe monotherapy is an effective and safe first-line treatment for children with heterozygous familial hypercholesterolemia, though combination with atorvastatin is needed for those with high baseline LDL-C.
Pshenichnikova et al. (2025) conducted an observational in Heterozygous familial hypercholesterolemia (heFH) (n=130). Ezetimibe vs. Baseline (intra-individual comparison) was evaluated on Change in LDL-C level from baseline after 3 months of ezetimibe monotherapy (MD -1.6 mmol/L, p=<0.05). Ezetimibe monotherapy for 3 months significantly reduced LDL-C levels by an average of 1.6 mmol/L (21.3%) from baseline in children with heterozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: